David Neal scientific summary

Urological research group

How do endocytic adaptor proteins (e.g. HIP1) interact with the androgen receptor and androgen response elements to modulate transcription?
To study the effects of a novel protein (LYRIC) on androgen function.
Evaluation of MCM5 as a biomarker in bladder and prostate cancer.
Cambridge is coordinating one of the two UK Specialised Programmes of Research Excellence (SPOREs) on translational prostate cancer (National Cancer Research Institute: £5.5m), which involve studies of the molecular pathology of advanced prostate cancer.
To determine the most effective treatment for early prostate cancer: the Prostate testing for cancer and Treatment (ProtecT) trial of case finding, funded through a £21m National Health Service Health Technology Assessment Programme (NHS HTA); 250,000 men are invited to be screened.
Men with prostate cancer are invited to enter a three-arm randomised clinical trial (RCT) of treatment and will be followed for 10 to 15 years. Tissue, blood and DNA are stored for studies of genetic epidemiology and proteomics.

To study the effects of adaptor proteins on AR signalling.
To identify novel androgen response elements.
Translational uro-oncology studies on tissue samples of novel proteins to determine use as bio-markers.
High throughput genetic epidemiology studies using the ProtecT biorepository.
To complete the ProtecT Trial.
To extend the bio-repository.